QUANTIB® Prostate

Read prostate MRI at expert level supported by AI

 

Quantib® Prostate is here to help you manage the increase in prostate MRI workload and streamline the radiology workflow.
The FDA cleared and CE marked zero-footprint artificial intelligence-based software provides a workflow for the detection of abnormalities on MRI prostate scans. 

 

Quantib Prostate movie

Man with prostate cancer schematic drawingYearly, 1.3M men are diagnosed with prostate cancer, often without the use of MRI, while NEJM and The Lancet report strong benefits of MRI.1,2

Prostate cancer MRI guidelines illustrative figureNew guidelines adopted by EAU and ACR advise to include MRI prior to all 3M biopsies taken yearly in Europe and the United States.3,4

Prostate cancer MRI increased workload illustrative figureRadiology practices already see a doubling in case load of multiparametric MRI prostate scans.

1 Taneja, S. S. et al. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N. Engl. J. Med. 378, 1767–1777 (2018).
2 Ahmed, H. U. et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 389, 815–822.
3 Andrew B. Rosenkrantz, M. et al. ACR - Prostate MRI Model Policy. Available at: https://www.acr.org/-/media/ACR/Files/Advocacy/AIA/Prostate-MRI-Model-Policy72219.pdf. (Accessed: 7th May 2020)
4 Mottet, N. et al. European Association of Urology - Prostate Cancer. 2020 Available at: https://uroweb.org/guideline/prostate-cancer/. (Accessed: 7th May 2020)

The current prostate MRI reading workflow is lengthy, labour-intensive and requires substantial practice to master.

Schematic representation of prostate cancer radiology pathway


What if you could have...

One solution,
one workflow

No more switching between PACS, PSA density calculation feature and PI-RADS support; Quantib® Prostate offers one workflow including all essential prostate MRI reading features.

AI-based support for
lesion assessment

Semi-automated combination of bi-parametric data supports ROI determination and enables prostate lesion evaluation. AI-bolstered segmentation allows for easy and fast determination of lesion volume.

Click-of-a-button
reporting

After prostate MRI assessment, a customized report is created including PSA density, quantified volumes, PI-RADS v.2.1 scoring and key images of suspicious regions. 

Product overview

Key features include

  • AI-driven prostate volume measurements
  • Integrated PSA density calculation
  • Fast, AI-supported ROI segmentation of suspicious areas
  • Visual PI-RADS v.2.1 scoring support
  • Export of prostate gland segmentation, ROIs and standardized report to PACS
  • A structured report including key images and visual representation of PI-RADS v.2.1 results
Learn More
prostate radiology software Quantib Prostate user interface on desktop monitor showing PIRADS scoring

Quantib® Prostate is currently 510(k) cleared by the FDA for distribution in the US. This product has been proven to conform to all requirements of the European Medical Device Regulations (2017/745) and is available in the EU and other countries. 

Curious to learn more about Quantib® Prostate? 

Learn from our resources

ULTIMATE GUIDE

AI in prostate cancer - homepage image

The Ultimate Guide to AI in Prostate Cancer

How does artificial intelligence work? What are promising AI applications in the prostate cancer pathway? Which solutions are available now?

Read more

VIDEO

P4 Tim

How AI can help with Quantification in Radiology

The benefits of AI for radiology are numerous. Tim Leiner, Professor of Radiology at the Department of Radiology, Utrecht University Medical Center in Utrecht, The Netherlands discusses how AI-powered tools can support the radiologists in their daily clinical workflow

WATCH VIDEO

LATEST POSTS

Advancing Alzheimer MRIs using AI-based quantitative imaging

Feb 25, 2021 4:15:00 PM BY Jordy Oudhuizen

6 use cases for CT body composition with AI

Jan 28, 2021 1:45:00 AM BY Pim Moeskops PhD, Wouter Veldhuis MD PhD and Prof. Tim Leiner MD

Subscribe for Updates